M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Bevacizumab
Drug: Lurbinectedin

First Posted Date: 2022-12-05

Last Posted Date: 2024-12-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT05636111

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Behavioral: Interview
Behavioral: Questionnaires

First Posted Date: 2022-12-02

Last Posted Date: 2024-08-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT05634551

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: MRTX849

First Posted Date: 2022-12-02

Last Posted Date: 2024-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT05634525

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Phase 2

Completed

Conditions: Adrenocortical Carcinoma

Interventions: Drug: Mitotane
Drug: Pembrolizumab

First Posted Date: 2022-12-02

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT05634577

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Valemetostat
Drug: Trastuzumab deruxtecan

First Posted Date: 2022-12-01

Last Posted Date: 2024-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT05633979

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Phase 2

Recruiting

Conditions: Lung Cancer

Interventions: Drug: NKTR-255
Drug: Durvalumab

First Posted Date: 2022-12-01

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT05632809

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects with Advanced/Metastatic Soft Tissue and Bone Sarcoma

Phase 1

Recruiting

Conditions: Soft Tissue Sarcoma
Bone Sarcoma

Interventions: Drug: Cyclophosphamide
Drug: attIL2-T cells

First Posted Date: 2022-11-18

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT05621668

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2

Recruiting

Conditions: B-Cell Lymphoma
Relapsed B-cell NHL
Hodgkin Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Polatuzumab vedotin
Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-11-14

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT05615636

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors

Not Applicable

Active, not recruiting

Conditions: Lung Cancer

Interventions: Radiation: Stereotactic MRI-guided adaptive radiotherapy-SMART
Other: Simulated Online Adaptive Planning

First Posted Date: 2022-11-08

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05609331

Locations: 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States

A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use

Phase 2

Withdrawn

Conditions: Cancer

Interventions: Device: Augmented Reality
Device: IPAD

First Posted Date: 2022-10-21

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05589857

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy